Tyr301
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr301  -  SIRT1 (human)

Site Information
QAMFDIEyFRKDPRP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 25311272

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
breast cancer ( 1 ) , colorectal cancer ( 1 ) , colorectal carcinoma ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , HCT116 (intestinal) ( 1 ) , Jurkat (T lymphocyte) ( 2 ) , MCF-10A (breast cell) ( 1 )

Upstream Regulation
Putative in vivo kinases:
JAK1 (human) ( 1 )
Treatments:
IL-6 ( 1 ) , PF-04965842 ( 1 )

Downstream Regulation
Effects of modification on SIRT1:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
transcription, inhibited ( 1 )
Induce interaction with:
STAT3 (human) ( 1 )

References 

1

Wang W, et al. (2018) JAK1-mediated Sirt1 phosphorylation functions as a negative feedback of the JAK1-STAT3 pathway. J Biol Chem
29789426   Curated Info

2

Possemato A (2008) CST Curation Set: 3661; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:pSXXXpS
Curated Info